Filtered By:
Drug: Bupropion

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 21 results found since Jan 2013.

Wants Talk Psychotherapy but Cannot Talk: EMDR for Post-stroke Depression with Expressive Aphasia
CONCLUSION This is the first reported case demonstrating that EMDR can be effective for depression, even in those with severe expressive aphasia. In our case, there was no reluctance to disclose information, simply a neurological inability to do so. Through preparation, patience, perseverance, and plasticity (clinician flexibility, though perhaps also neuroplasticity), the patient’s PSD gradually improved, and she was able to reinvent her life within her limitations. ACKNOWLEDGMENTS The authors gratefully acknowledge Eugene Schwartz, E.C. Hurley, and Mark Hubner for providing consultation during patient care. REFERENCES ...
Source: Innovations in Clinical Neuroscience - February 1, 2018 Category: Neuroscience Authors: ICN Online Editor Tags: Case Report Current Issue Neurologic Systems and Symptoms Neurology Psychotherapy Stroke aphasia depression EMDR Source Type: research

Modafinil for the Improvement of Patient Outcomes Following Traumatic Brain Injury
Conclusion. Modafinil is a central nervous system stimulant with well-established effectiveness in the treatment of narcolepsy and shift-work sleep disorder. There is conflicting evidence about the benefits of modafinil in the treatment of fatigue and EDS secondary to TBI. One randomized, controlled study states that modafinil does not significantly improve patient wakefulness, while another concludes that modafinil corrects EDS but not fatigue. An observational study provides evidence that modafinil increases alertness in fatigued patients with past medical history of brainstem diencephalic stroke or multiple sclerosis. ...
Source: Innovations in Clinical Neuroscience - April 1, 2018 Category: Neuroscience Authors: ICNS Online Editor Tags: Current Issue Review excessive daytime sleep fatigue head injury modafinil stroke TBI traumatic brain injury Source Type: research

Antidepressant Medication Use and Its Association With Cardiovascular Disease and All-Cause Mortality in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study.
CONCLUSIONS: In fully adjusted models, antidepressant use was associated with a small increase in all-cause mortality. PMID: 26783360 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - January 18, 2016 Category: Drugs & Pharmacology Authors: Hansen RA, Khodneva Y, Glasser SP, Qian J, Redmond N, Safford MM Tags: Ann Pharmacother Source Type: research

Is bupropion useful in the treatment of post-stroke thalamic apathy? A case report and considerations.
Authors: Aragona B, De Luca R, Piccolo A, Le Cause M, Destro M, Casella C, Filoni S, Calabrò RS Abstract Post-stroke apathy is considered to be one of the clinical consequences of lesions affecting the structures of the prefrontal cortex, basal ganglia, thalamus and limbic system. However, there is no current consensus on the treatment of post-stroke apathy, which mainly depends on the underlying etiology and comorbidities. A 62-year-old man, affected by hemorrhagic stroke in the left thalamus, presented with mood depression, anhedonia, hyporexia and marked apathy. The patient underwent clinical evaluation before ...
Source: Functional Neurology - January 23, 2019 Category: Neurology Tags: Funct Neurol Source Type: research

Cardiovascular and mortality risks in older Medicare patients treated with varenicline or bupropion for smoking cessation: an observational cohort study
ConclusionCardiovascular and mortality risks were not increased in older patients treated with varenicline compared with bupropion for smoking cessation. A potential increase in the risk of stroke with varenicline could not be excluded. Treatment persistence with either drug was low. Published 2014. This article is a U.S. Government work and is in the public domain in the USA.
Source: Pharmacoepidemiology and Drug Safety - July 5, 2014 Category: Drugs & Pharmacology Authors: David J. Graham, Kunthel By, Stephen McKean, Andrew Mosholder, Cynthia Kornegay, Judith A. Racoosin, Jessica Young, Mark Levenson, Thomas E. MaCurdy, Chris Worrall, Jeffrey A. Kelman Tags: Original Report Source Type: research

Probable Nootropic-induced Psychiatric Adverse Effects: A Series of Four Cases
Conclusion Healthcare providers in general, and specifically those in the mental health and substance abuse fields, should keep in mind that nootropic use is an under recognized and evolving problem. Nootropic use should be considered in cases where there are sudden or unexplained exacerbations of psychiatric symptoms in patients who have been stable and medication adherent. It is also important to remember that most nootropics are not detected on standard drug toxicology screening tests. We have very little clinical information on how nootropics may interact with psychotropics (or other medications) and potentially cause ...
Source: Innovations in Clinical Neuroscience - December 1, 2015 Category: Neuroscience Authors: ICN Online Editor Tags: Case Series and Literature Review Current Issue Mental Disorders Psychiatry Psychopharmacology Substance Use Disorders Ampakines Armodafinil brain enhancer Cerebrolysin Citicoline cognitive enhancer homeopathic medicine natural r Source Type: research

Correlates of former smoking in patients with cerebrovascular disease: a cross-sectional study
Conclusions There are multilevel correlates of former smoking in smokers with reported stroke symptoms. These correlates include older age groups, higher education, household and vehicle smoking restrictions, pharmacotherapy use (bupropion), access to a general practitioner and counselling advice from a physician.
Source: BMJ Open - January 21, 2015 Category: Journals (General) Authors: Edjoc, R. K., Reid, R. D., Sharma, M., Balfour, L., Procino, M. Tags: Open access, Epidemiology, Smoking and tobacco Research Source Type: research

Annual budgetary impact of varenicline as part of a smoking cessation strategy in Greece
Conclusions: Varenicline reimbursement may represent a balanced strategy from a budget impact perspective in Greece even taking into account hospital resource utilization only.
Source: European Respiratory Journal - October 30, 2015 Category: Respiratory Medicine Authors: Katsaounou, P., Bilitou, A., Tsekouras, V. Tags: 6.3 Tobacco, Smoking Control and Health Education Source Type: research

CNS Summit 2017 Abstracts of Poster Presentations
Conclusion: This novel technology discriminates and quantifies subtle differences in behavior and neurological impairments in subjects afflicted with neurological injury/disease. KINARM assessments can be incorporated into multi-center trials (e.g., monitoring stroke motor recovery: NCT02928393). Further studies will determine if KINARM Labs can demonstrate a clinical effect with fewer subjects over a shorter trial period. Disclosures/funding: Dr. Stephen Scott is the inventor of KINARM and CSO of BKIN Technologies.   Multiplexed mass spectrometry assay identifies neurodegeneration biomarkers in CSF Presenter: Chelsky...
Source: Innovations in Clinical Neuroscience - November 1, 2017 Category: Neuroscience Authors: ICNS Online Editor Tags: Assessment Tools biomarkers Cognition Current Issue Drug Development General Genetics Medical Issues Neurology Patient Assessment Psychopharmacology Scales Special Issues Supplements Trial Methodology clinical trials CNS Su Source Type: research

A Non-Epileptiform Event in the Course of rTMS: A Case for Close Physician Monitoring
We present the following case to demonstrate the importance of having physician supervision of patients undergoing repetitive transcranial magnetic stimulation (rTMS) treatments. The patient was a married 60-year-old male with a diagnosis of Major Depressive Disorder and Generalized Anxiety Disorder who had continuous symptoms of depression since the early 1980s despite receiving at least 7 adequate antidepressant treatments. The patient had several comorbid medical conditions. The patient did not have any previous history of seizure, stroke, an abnormal EEG, head injury, neurosurgical procedure, implanted devices, frequen...
Source: BRAIN STIMULATION: Basic, Translational, and Clinical Research in Neuromodulation - April 29, 2013 Category: Neurology Authors: F. Andrew Kozel, Paul E. Croarkin, Kimberly S. Mapes Tags: Letters to the Editor Source Type: research

'No serious heart risks' linked to smoking cessation therapies
The American Heart Association claims that three different types of smoking cessation therapies do not pose serious heart risks, quashing concerns that certain products may increase the risks of heart attack, stroke or heart-related death.Researchers looked at the results of 63 clinical trials involving 30, 508 people who were quitting smoking using either nicotine replacement gums and patches, the nicotine addiction treatment varenicline (Chantix), or taking the antidepressant bupropion (Wellbutrin), which can reduce cravings and other unwanted withdrawal effects.
Source: Health News from Medical News Today - December 13, 2013 Category: Consumer Health News Tags: Smoking / Quit Smoking Source Type: news

Study: Nicotine Patch Works as Well as Chantix to Help Quit Smoking
This study confirms that FDA-approved medications are effective in helping smokers quit,” said Lee Westmaas, PhD, American Cancer Society director of tobacco control research. “Smokers should seriously consider using medications if they are finding it difficult to quit without any help. The most effective approach to quitting is using medications in combination with counseling such as from a quit-line.”RESOURCES: How to Quit Smoking Quit-smoking medicationsResearch shows that using a medication to help you quit smoking can double your chances of being successful.The US Food and Drug Administration (...
Source: American Cancer Society :: News and Features - February 2, 2016 Category: Cancer & Oncology Tags: Smoking/Tobacco Source Type: news

Evolution of Pharmacological Obesity Treatments: Focus on Adverse Side‐Effect Profiles
ABSTRACT Pharmacotherapy directed toward reducing body weight may provide benefits for both curbing obesity and lowering the risk of obesity‐associated co‐morbidities. However, many weight loss medications have been withdrawn from the market due to serious adverse effects. Examples include pulmonary hypertension (aminorex), cardiovascular toxicity, e.g. flenfluramine‐induced valvopathy, stroke (phenylpropanolamine), excess non‐fatal cardiovascular events (sibutramine), and neuro‐psychiatric issues (rimonabant ‐ approved in Europe, but not in the US). This negative experience has helped mold the current drug dev...
Source: Diabetes, Obesity and Metabolism - March 1, 2016 Category: Endocrinology Authors: Andrew J. Krentz, Ken Fujioka, Marcus Hompesch Tags: REVIEW ARTICLE Source Type: research

Pharmacologic Approaches to Weight Management: Recent Gains and Shortfalls in Combating Obesity
This article reviews recent literature in the field of Obesity Medicine and highlights important findings from clinical trials. Future directions in the pharmacologic management of obesity are presented along with new diabetes medications that promote weight loss and reduce cardiovascular mortality.
Source: Current Atherosclerosis Reports - May 14, 2016 Category: Cardiology Source Type: research

How to Quit Smoking
By Stacy Simon Tobacco use remains the single largest preventable cause of disease and premature death in the United States. Since the release of the Surgeon General’s Report on Smoking and Health 50 years ago, there have been 20 million deaths due to tobacco. Almost half the deaths from 12 different types of cancer combined – including lung, voice box, throat, esophagus, and bladder cancers – are attributable to cigarette smoking alone. In addition to cancer, smoking greatly increases the risk of debilitating long-term lung diseases like emphysema and chronic bronchitis. It also raises the risk for heart...
Source: American Cancer Society :: News and Features - November 16, 2016 Category: Cancer & Oncology Tags: Smoking/Tobacco Source Type: news